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Abstract: Wegener’s granulomatosis (WG) is a necrotizing granulomatous vasculitis character-
ized by the involvement of the upper or lower airways, lungs, and kidneys, but it can affect almost 
any organ including the orbit. WG is rare in childhood. This case report describes a 7-year-old 
girl who presented bilateral idiophatic orbital inﬂ  ammation and antineutrophil cytoplasmic 
antibodies-negative titres. Computed tomography scan and magnetic resonance imaging showed 
enlargement of both lacrimal glands with inﬁ  ltration. Treatment with corticosteroids achieved 
remission of the disease. Three years later, she developed a systemic affectation with tracheal 
stenosis, pulmonary affectation, renal failure, and respiratory tract mucosa inﬂ  ammation. 
Lacrimal gland biopsy showed perivascular nonspeciﬁ  c granulomas and ANCA titres remain 
negative. Treatment with corticosteroids and cyclophosphamide was done. A relapse occurred 
2 years later, with complete remission with antitumor necrosis factor-alpha. No other symptoms 
have appeared after 9 years of follow-up. Early diagnosis and treatment is crucial to increase 
the survival rate in these patients.
Keywords: ANCA, children, idiopathic orbital inﬂ  ammation, exophthalmos, vasculitis, 
Wegener’s granulomatosis
Introduction
Wegener’s granulomatosis (WG) is a chronic inﬂ  ammatory autoimmune disease of 
unknown etiology. It is a multisystem necrotizing vasculitis that primarily involves 
the upper and lower respiratory tract and kidneys but it can affect almost any organ, 
including the orbit and eye. The involvement of the upper airway is the most com-
mon symptom though kidney involvement can be the ﬁ  rst one. WG in children is a 
rare disease.
Only one case has been described previously with cytoplasmic antineutrophil 
cytoplasmic antibodies (ANCA)-negative titres in the orbit in a child; it was a case 
of idiophatic orbital inﬂ  ammation (IOI), also known as orbital pseudotumor (Wardyn 
et al 2003). However, a few cases in childhood with positive ANCA (Ziakas et al 2004) 
have been described.
Case report
A 7-year-old girl presented with a acute mild proptosis of the left eye pain, along with 
downwards and medial displacement of the globe and eyelid swelling (Figure 1A), but 
no diplopia or visual loss. The patient also showed chronic nonspeciﬁ  c constitutional 
symptoms such as weight loss and height below normal limits. Family history included 
mother with rheumatoid arthritis. In a few weeks the clinical signs progressed to both 
orbits. Orbital computed tomography scan (Figure 1B) and magnetic resonance imaging 
showed inﬁ  ltration and enlargement of both lacrimal glands and sinusitis. Chest X-Clinical Ophthalmology 2008:2(4) 942
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rays were normal. Immunologic studies showed negative 
cytoplasmic ANCA and perinuclear ANCA; immunoﬂ  uo-
rescence and speciﬁ  ties were conﬁ  rmed by antiproteinase 
3, and antimyeloperoxidase. Antinuclear antibodies were 
positive to a 1/160 dilution (1/20–1/40). C-reactive protein 
was 0.3 mg/dL (0.0–0.8), rheumatoid factor 20 IU/mL 
(0–30), erythrocyte sedimentation rate 18 mm/h (0–20), 
and creatinine clearance was 95 mL/min/1.73 m2 (88–128). 
Urinanalysis showed normal results. Incisional biopsy of 
the lacrimal gland showed a nonspeciﬁ  c lymphoplasmacytic 
inﬁ  ltrate consistent with IOI. Immunohistochemical stud-
ies showed positive CCA, MAC387, lisozyme, and CD68. 
Special stains for micro-organisms such as fungi and aci-
fast bacteria were negative. Hepatitis B and C infections 
and human immunodeﬁ  ciency virus tests were negative. 
Treatment with corticosteroids, prednisone 1 mg/kg/day for 
3 weeks orally and then a tapered dosage to zero over 12 
weeks, obtained remission of the disease with disappear-
ance of the orbital symptoms. After 3 years without signs 
or symptoms, she presented again with the previous ocular 
symptoms, but also subglottic tracheal stenosis and bilateral 
basal pulmonary inﬁ  ltrates, as well as decreased renal func-
tion (47 mL/min/1.73 m2), and erithrocyte sedimentation 
rate of 77. Incisional biopsies of the lacrimal gland, nasal 
and oral mucosa showed non-speciﬁ  c histiocytic inﬁ  ltrate 
with a large compound of plasmacytoid, lymphocytes and 
eosinophilic cells without anaplasia. The acinar compound 
of the lacrimal gland was destroyed and the cell inﬁ  ltrate was 
located in a perivascular and periductal disposition, with a 
granulomatous aspect (Figure 2). The ANCA titres remained 
Figure 1A Patient at presentation showed eyelid swelling with downward and medial displacement of the eye on the left side. B Coronal magnetic resonance imaging showed 
enlarged lacrimal glands.Clinical Ophthalmology 2008:2(4) 943
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within normal limits. At that moment WG was established as 
a diagnostic, and treatment with oral prednisone 1mg/kg/day, 
intravenous cyclophosphamide 0.7 gr/m2/month/12 months, 
0.5 gr/m2/month/2 months induced remission of the disease. 
Two years later the patient presented a relapse with new 
orbital IOI, tracheal stenosis and pulmonary inﬁ  ltrates, and 
the treatment applied was an antitumor necrosis factor-alpha 
(TNF-α), inﬂ  iximab 5 mg/kg six infusions for 34 weeks, 
which stabilized the clinical course. After a follow-up of 8 
years, the patient is free from any sign of the disease.
Discussion
WG is a systemic granulomatous vasculitis that typically 
affects the upper airways, lungs, and kidneys. This form of vas-
culitis is extremely rare in children, the most common form of 
pediatric systemic vasculitis being Henoch-Schonlein purpura. 
In the two published case series, the disease was more frequent 
in females than in males with a proportion (3:1) (Reinhold-
Keller et al 2001; Fechner et al 2002). Ophthalmic involve-
ment is relatively common in the course of the disease and 
may in fact be the initial presenting feature in some patients. 
It is therefore imperative to considerer WG in the differential 
diagnosis when more common disorders are ruled out.
In these patients it is important to rule out the existence 
of hepatitis B and hepatitis C infections, human immuno-
deﬁ  ency virus, immunodeﬁ  ciency disorders, and malignant 
diseases, which can produce similar manifestations. Nowa-
days there are data that suggest a possible toxic exposure, 
which should be a potentially correctable risk factor (Albert 
et al 2005). WG is commonly ANCA-positive but some cases 
may be ANCA-negative (Langford 1998). WG in the systemic 
form is commonly cytoplasmic ANCA-positive (95%), while 
the localized form is usually negative to cytoplasmic ANCA 
and highly positive to perinuclear ANCA. WG with ANCA 
has led to its designation as ANCA-associated vasculitis. 
However, there are patients without ANCA whose clinical 
and pathological features meet both the American College 
of Rheumatology 1990 (Leavitt et al 1990) classiﬁ  cation 
criteria for WG and the 1993 (Jennette et al 1994) Chapel 
Hill Consensus Conference on the Nomenclature of Systemic 
Vasculitis deﬁ  nition of WG. Only 14 cases of active general-
ized WG without ANCA have been described in the English 
literature and one in a girl presenting with episcleritis. It is 
remarkable that most of these patients had cerebral and/or 
meningeal involvement, but none presented orbital involve-
ment (Reinhold-Keller et al 2001).
Histological evaluation usually shows an acute and chronic 
inﬂ  ammation, necrotizing vasculitis, poorly formed granulo-
mas, microabscesses, and ﬁ  brinoid degeneration of collagen. 
Nevertheless, the presence of these ﬁ  ndings can vary greatly, 
and small biopsies, especially from the head and neck region, 
often lack all of them. Therefore, the diagnosis of WG must 
rest on the ﬁ  nding of a constellation of histological and clinical 
features (Pakrou et al 2006).
The disease is usually fatal if untreated, although WG 
limited to the orbit and adnexal structures without systemic 
Figure 2 Histopathological examination of lacrimal gland: lymphoplasmacytoid inﬁ  ltrate with perivascular granulomas (hematoxylin-eosin, 40×).Clinical Ophthalmology 2008:2(4) 944
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involvement have a good overall prognosis. The prevention 
of relapses and treatment of refractory cases remain the 
greatest challenges in the treatment of WG (Hellmich et al 
2006). Open-label clinical studies suggest a beneﬁ  cial 
effect of anti-TNF-α, inﬂ  iximab, in addition to standard 
therapy in refractory WG. In contrast, a recent randomized 
controlled trial showed an increased risk of serious infec-
tions and a dose-dependent increased anti-TNF antibody 
therapy, with higher dosages leading to more remissions 
(WGET 2005; Hellmich et al 2006; Bongartz et al 2006). 
The combination of TNF inhibition and cyclophosphamide 
may heighten the risk of cancer beyond that observed with 
cyclosphophamide alone; six cases of solid cancer have 
been identiﬁ  ed with the use of etanercept (Stone et al 
2006) and the development of a lymphoma with inﬂ  iximab 
(Booth et al 2004). Inﬂ  iximab represents a new therapeutic 
option and offers better perspectives for a patient group 
with a previously bad prognosis (Bartolucci et al 2002). 
However, the current data are conﬂ  icting and difﬁ  cult to 
interpret. As a result, the newer agents cannot be recom-
mended for routine use until a vigorous clinical study 
conﬁ  rms their efﬁ  cacy (White and Lynch 2006). While 
early diagnosis and treatment with immunosuppressives 
such as cyclophosphamide can induce long term remis-
sion, there are also serious toxicities associated (Fauci 
and Wolff 1973). Treatment for maintenance of remission 
is mandatory.
Our case consisted in a bilateral IOI of the lacrimal gland. 
WG must be considered in this condition, but the absence 
of systemic involvement or necrotizing granulomas in the 
biopsy and the negativity of ANCA made conﬁ  rmation of the 
diagnosis impossible. Futhermore, WG rarely affects chil-
dren and most of the published cases were ANCA-positive. 
Although there may be ANCA-negative cases in children, 
the diagnosis is difﬁ  cult if the histological features are not 
speciﬁ  c to the disease.
We also point out the lack of aggressiveness of this case, 
despite its late diagnosis three years after the initial manifes-
tation, and the good response to inﬂ  iximab, with no relapses 
after 8 years of follow-up.
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